Steatohepatitis/Metabolic Liver Disease News

Healio Gastroenterology presents the following reports on recent news in COVID-19.

Terns Pharmaceuticals Inc. announced initiation of a phase 1b clinical trial assessing TERN-201 for the treatment of patients with nonalcoholic steatohepatitis.

Healio Gastroenterology presents the following report on the top peer-tested stories in June.

Terns Pharmaceuticals Inc. announced positive topline results from the phase 2a Lift study of TERN-101 for the treatment of patients with nonalcoholic steatohepatitis.

Icosabutate improved markers of liver injury, inflammation and fibrosis in patients with nonalcoholic steatohepatitis, according to a study presented at The International Liver Congress.

Endoscopic sleeve gastroplasty in patients with nonalcoholic steatohepatitis vs. life-style intervention alone was safe and effective for achieving weight loss correlated with significant improvements, according to a presentation at the International Liver Congress.

Among patients with FIB-4 nonalcoholic steatohepatitis at greater risk for progression to end stage liver disease, researchers at the International Liver Congress found efruxifermin 50 mg was safe and well-tolerated.

A study from Israel, where vaccination for COVID reached most of the population older than 16 years, showed older patients, post-transplant patients and those with advanced liver disease produced less immune response to the Pfizer COVID-19 vaccine.

Among patients with nonalcoholic fatty liver disease and advanced fibrosis, food insecurity significantly correlated with greater all-cause mortality, according to a presenter at the International Liver Congress.

Using clinical bloodwork like FIB-4 and elastography technology in combination, Researchers at the International Liver congress proposed they could better identify patients with advanced fibrosis using clinical bloodwork like FIB-4 and elastography technology in combination.